Clinical Trials · NCT06717698
A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease
- Phase
- Phase 2
- Recruitment status
- Recruiting
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 465
- Start date
- Dec 2024
- Locations
- 147 sites, 14 countries
- Primary endpoint
- Change in urinary albumin-to-creatinine ratio (UACR) at week 12